BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 31865062)

  • 21. Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma.
    He Y; Li J; Ding N; Wang X; Deng L; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Song Y; Zhu J
    J Exp Clin Cancer Res; 2019 Feb; 38(1):86. PubMed ID: 30777096
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.
    Erdmann T; Klener P; Lynch JT; Grau M; Vočková P; Molinsky J; Tuskova D; Hudson K; Polanska UM; Grondine M; Mayo M; Dai B; Pfeifer M; Erdmann K; Schwammbach D; Zapukhlyak M; Staiger AM; Ott G; Berdel WE; Davies BR; Cruzalegui F; Trneny M; Lenz P; Barry ST; Lenz G
    Blood; 2017 Jul; 130(3):310-322. PubMed ID: 28202458
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bruton's tyrosine kinase inhibition induces rewiring of proximal and distal B-cell receptor signaling in mice.
    Rip J; de Bruijn MJW; Neys SFH; Singh SP; Willar J; van Hulst JAC; Hendriks RW; Corneth OBJ
    Eur J Immunol; 2021 Sep; 51(9):2251-2265. PubMed ID: 34323286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of BLNK and BTK as mediators of rituximab-induced programmed cell death by CRISPR screens in GCB-subtype diffuse large B-cell lymphoma.
    Thomsen EA; Rovsing AB; Anderson MV; Due H; Huang J; Luo Y; Dybkaer K; Mikkelsen JG
    Mol Oncol; 2020 Sep; 14(9):1978-1997. PubMed ID: 32585766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical evidence for the effective use of TL-895, a highly selective and potent second-generation BTK inhibitor, for the treatment of B-cell malignancies.
    Goodstal SM; Lin J; Crandall T; Crowley L; Bender AT; Pereira A; Soloviev M; Wesolowski JS; Iadevaia R; Schelhorn SE; Ross E; Morandi F; Ma J; Clark A
    Sci Rep; 2023 Nov; 13(1):20412. PubMed ID: 37989777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Toll-Like Receptor Signaling Drives Btk-Mediated Autoimmune Disease.
    Rip J; de Bruijn MJW; Appelman MK; Pal Singh S; Hendriks RW; Corneth OBJ
    Front Immunol; 2019; 10():95. PubMed ID: 30761150
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Responses to the Selective Bruton's Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines.
    Kozaki R; Vogler M; Walter HS; Jayne S; Dinsdale D; Siebert R; Dyer MJS; Yoshizawa T
    Cancers (Basel); 2018 Apr; 10(4):. PubMed ID: 29690649
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies.
    Kapoor I; Li Y; Sharma A; Zhu H; Bodo J; Xu W; Hsi ED; Hill BT; Almasan A
    Cell Death Dis; 2019 Dec; 10(12):924. PubMed ID: 31801949
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.
    Yang G; Wang J; Tan L; Munshi M; Liu X; Kofides A; Chen JG; Tsakmaklis N; Demos MG; Guerrera ML; Xu L; Hunter ZR; Che J; Patterson CJ; Meid K; Castillo JJ; Munshi NC; Anderson KC; Cameron M; Buhrlage SJ; Gray NS; Treon SP
    Blood; 2021 Nov; 138(20):1966-1979. PubMed ID: 34132782
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma.
    Goldstein RL; Yang SN; Taldone T; Chang B; Gerecitano J; Elenitoba-Johnson K; Shaknovich R; Tam W; Leonard JP; Chiosis G; Cerchietti L; Melnick A
    J Clin Invest; 2015 Nov; 125(12):4559-71. PubMed ID: 26529251
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
    Sibaud V; Beylot-Barry M; Protin C; Vigarios E; Recher C; Ysebaert L
    Am J Clin Dermatol; 2020 Dec; 21(6):799-812. PubMed ID: 32613545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma.
    Milhollen MA; Traore T; Adams-Duffy J; Thomas MP; Berger AJ; Dang L; Dick LR; Garnsey JJ; Koenig E; Langston SP; Manfredi M; Narayanan U; Rolfe M; Staudt LM; Soucy TA; Yu J; Zhang J; Bolen JB; Smith PG
    Blood; 2010 Sep; 116(9):1515-23. PubMed ID: 20525923
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.
    Wilson WH; Young RM; Schmitz R; Yang Y; Pittaluga S; Wright G; Lih CJ; Williams PM; Shaffer AL; Gerecitano J; de Vos S; Goy A; Kenkre VP; Barr PM; Blum KA; Shustov A; Advani R; Fowler NH; Vose JM; Elstrom RL; Habermann TM; Barrientos JC; McGreivy J; Fardis M; Chang BY; Clow F; Munneke B; Moussa D; Beaupre DM; Staudt LM
    Nat Med; 2015 Aug; 21(8):922-6. PubMed ID: 26193343
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy.
    Kelly PN; Romero DL; Yang Y; Shaffer AL; Chaudhary D; Robinson S; Miao W; Rui L; Westlin WF; Kapeller R; Staudt LM
    J Exp Med; 2015 Dec; 212(13):2189-201. PubMed ID: 26621451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib.
    Ninomiya K; Ohashi K; Makimoto G; Tomida S; Higo H; Kayatani H; Ninomiya T; Kubo T; Ichihara E; Hotta K; Tabata M; Maeda Y; Kiura K
    Sci Rep; 2018 Jan; 8(1):1955. PubMed ID: 29386539
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.
    Dunleavy K; Pittaluga S; Czuczman MS; Dave SS; Wright G; Grant N; Shovlin M; Jaffe ES; Janik JE; Staudt LM; Wilson WH
    Blood; 2009 Jun; 113(24):6069-76. PubMed ID: 19380866
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma.
    Ding N; Li X; Shi Y; Ping L; Wu L; Fu K; Feng L; Zheng X; Song Y; Pan Z; Zhu J
    Oncotarget; 2015 Jun; 6(17):15122-36. PubMed ID: 25944695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKT.
    Paul J; Soujon M; Wengner AM; Zitzmann-Kolbe S; Sturz A; Haike K; Keng Magdalene KH; Tan SH; Lange M; Tan SY; Mumberg D; Lim ST; Ziegelbauer K; Liu N
    Cancer Cell; 2017 Jan; 31(1):64-78. PubMed ID: 28073005
    [TBL] [Abstract][Full Text] [Related]  

  • 39. B-cell receptor signaling in diffuse large B-cell lymphoma.
    Young RM; Shaffer AL; Phelan JD; Staudt LM
    Semin Hematol; 2015 Apr; 52(2):77-85. PubMed ID: 25805587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disrupting myddosome assembly in diffuse large B‑cell lymphoma cells using the MYD88 dimerization inhibitor ST2825.
    Wang X; Tan Y; Huang Z; Huang N; Gao M; Zhou F; Hu J; Feng W
    Oncol Rep; 2019 Nov; 42(5):1755-1766. PubMed ID: 31432184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.